Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report

RATIONALE: Mesenchymal-to-epithelial transition (MET) exon 14 skipping mutation was a targetable alteration in nonsmall-cell lung cancer (NSCLC), and the MET inhibitor of crizotinib had the most efficacy among all the targeted drugs. Most of the cancer-related deaths are associated with metastasis....

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Xiang, Dai, Lei, Wang, Yongyong, Liang, Guanbiao, Yang, Nuo, Chen, Mingwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708966/
https://www.ncbi.nlm.nih.gov/pubmed/29381967
http://dx.doi.org/10.1097/MD.0000000000008744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708966/
https://www.ncbi.nlm.nih.gov/pubmed/29381967
http://dx.doi.org/10.1097/MD.0000000000008744

Ejemplares similares